Furthermore, its capacity to block Akt-mTOR activation significantly hindered the growth of osteosarcoma xenografts in nude mice, indicating the potential therapeutic value of concurrent mTORC1/2 inhibition with XL388 in osteosarcoma treatment (44). This evidence concerns the gene MTOR and osteosarcoma.